Cargando…

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales: Tice, Jeffrey A, Touchette, Daniel R, Lien, Pei-Wen, Agboola, Foluso, Nikitin, Dmitriy, Pearson, Steven D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/
https://www.ncbi.nlm.nih.gov/pubmed/34949112
http://dx.doi.org/10.18553/jmcp.2022.28.1.119
_version_ 1785078473425944576
author Tice, Jeffrey A
Touchette, Daniel R
Lien, Pei-Wen
Agboola, Foluso
Nikitin, Dmitriy
Pearson, Steven D
author_facet Tice, Jeffrey A
Touchette, Daniel R
Lien, Pei-Wen
Agboola, Foluso
Nikitin, Dmitriy
Pearson, Steven D
author_sort Tice, Jeffrey A
collection PubMed
description
format Online
Article
Text
id pubmed-10373007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103730072023-07-31 The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council Tice, Jeffrey A Touchette, Daniel R Lien, Pei-Wen Agboola, Foluso Nikitin, Dmitriy Pearson, Steven D J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2022-01 /pmc/articles/PMC10373007/ /pubmed/34949112 http://dx.doi.org/10.18553/jmcp.2022.28.1.119 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Perspectives on Value
Tice, Jeffrey A
Touchette, Daniel R
Lien, Pei-Wen
Agboola, Foluso
Nikitin, Dmitriy
Pearson, Steven D
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_full The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_fullStr The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_full_unstemmed The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_short The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
title_sort effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: a summary from the institute for clinical and economic review’s new england comparative effectiveness public advisory council
topic Perspectives on Value
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373007/
https://www.ncbi.nlm.nih.gov/pubmed/34949112
http://dx.doi.org/10.18553/jmcp.2022.28.1.119
work_keys_str_mv AT ticejeffreya theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT touchettedanielr theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT lienpeiwen theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT agboolafoluso theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT nikitindmitriy theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT pearsonstevend theeffectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT ticejeffreya effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT touchettedanielr effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT lienpeiwen effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT agboolafoluso effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT nikitindmitriy effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil
AT pearsonstevend effectivenessandvalueofeculizumabandefgartigimodforgeneralizedmyastheniagravisasummaryfromtheinstituteforclinicalandeconomicreviewsnewenglandcomparativeeffectivenesspublicadvisorycouncil